All In Biotech

Drug Trial Radar · NCT05041907

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,800

Planned (sponsor's estimate)

Start

Sep 30, 2021

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment): A: Small molecule drugs; B: Monoclonal antibodies; C: Dose finding for the constituent parts of nirmatrelvir/ritonavir PLATCOV study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.

Conditions

  • COVID-19

Interventions

  • Nirmatrelvir/ritonavir (e.g. PAXLOVID™)Drug

    Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7

  • NitazoxanideDrug

    Nitazoxanide 1.5g BD 7/7

  • Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)Drug

    Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7

  • HydroxychloroquineDrug

    Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7

  • No treatmentOther

    No treatment (except antipyretics- paracetamol)

  • Monoclonal antibodiesDrug

    Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0

  • FluoxetineDrug

    Fluoxetine 40mg OD for 7/7

  • MolnupiravirDrug

    Molnupiravir 800mg BD for 5/7

  • SotrovimabDrug

    Sotrovimab 500mg given once on D0

  • EnsitrelvirDrug

    Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7

  • Monoclonal antibodiesDrug

    Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0

  • FavipiravirDrug

    Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7

  • IvermectinDrug

    Ivermectin 600micrograms/kg/day for 7/7.

  • RemdesivirDrug

    Remdesivir 200mg D0 and 100mg for a further 4/7.

  • Atilotrelvir/ritonavirDrug

    Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7

  • MetforminDrug

    Metformin 500mg TDS 5/7

  • Nirmatrelvir/ritonavirDrug

    Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7

  • Nirmatrelvir/ritonavirDrug

    Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7

  • NirmatrelvirDrug

    Nirmatrelvir 300mg BD for 5/7

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of viral clearance for interventions relative to the no study arm (This is a superiority comparison)Time frame: Days 0-5
  2. Rate of viral clearance for interventions relative to the positive control arm (This is a non-inferiority or superiority comparison).Time frame: Days 0-5

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Universidade Federal de Minas Gerais

    Minas Gerais, Brazil · Recruiting

  • Laos-Oxford-Mahosot Wellcome Trust Research Unit

    Vientiane, Laos · Recruiting

  • Sukraraj Tropical & Infectious Disease Hospital

    Kathmandu, Nepal · Recruiting

  • The Aga Khan University Hospital

    Karachi, Pakistan · Terminated

  • Vajira hospital

    Bangkok, Thailand · Terminated

  • Faculty of Tropical Medicine, Mahidol University

    Bangkok, Thailand · Recruiting

  • Bangplee Hospital

    Mueang Samut Prakan, Thailand · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.